ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0007171;activation of transmembrane receptor protein tyrosine kinase activity;12.0;1.0;0.9481203125901445;9.628524252492122;1143.6879814690685;7.212124270218933;0.03827820748741112;0.8169486831672182;[EGF, PDGFC, ADRB2]
GO:2000480;negative regulation of cAMP-dependent protein kinase activity;12.0;1.0;0.9481203125901445;9.628524252492122;1429.0529900327056;7.697632086000634;0.04782911751220199;0.8417775754447168;[PRKAR1B, PRKAR2B, PKIG]
GO:0018108;peptidyl-tyrosine phosphorylation;9.0;0.811012628672052;0.801746939516315;9.414950152194063;338.33129968976414;4.530049555519983;0.011323644122215096;0.627907570118429;[IL5RA, SLA2, FGF5, EFEMP1, GRAP2, EPHB1, PDGFRB, MAP2K2, BTC, MELK, BTK, EPHA3, BLK, CSF2RB, MAP2K6, LYN, BMX, CLK4, PTK2, CLK1, ITK, GHR, SYK, FGR, ZAP70, HCK, LCK, KIT, HBEGF, FYN, CSK, IL12RB2, EGF, TIE1, WEE1, PTPN6, TEK]
GO:0003091;renal water homeostasis;7.0;1.0;0.8509193652572005;9.628524252492122;57.14336741787613;6.311337724880743;0.0019125370817844765;0.6736814700148209;[WFS1, CYP4F2, ADCY9, PRKAR1B, PRKAR2B, PRKACB]
GO:0034199;activation of protein kinase A activity;12.0;1.0;0.9481203125901445;9.628524252492122;1099.1709144601095;7.57984905034425;0.03678826131738048;0.835754145523778;[PRKAR1B, PRKAR2B, PRKACB]
GO:0007173;epidermal growth factor receptor signaling pathway;9.0;0.7763722522362496;0.7844267512984139;9.040737587590003;32.38857880465376;5.788089581116195;0.0010840165847632744;0.6922437955322635;[TGFA, SLC30A10, EPS8, EFEMP1, REPS2, AKT1, PLCG1, TGFB1, EGF, GAB1, PTK2, BTC, KIF16B, HBEGF]
GO:0046854;phosphatidylinositol phosphorylation;8.0;1.0;0.875;9.628524252492122;218.7418113453505;5.049685808968129;0.007321091570879569;0.6332411671050352;[CD86, CD80, SLA2, FGF5, IMPA2, PDGFRB, GAB1, TTC7B, VAV1, BTC, LCK, KIT, HBEGF, CD19, FYN, ICOS, TRAT1, EGF, CD28]
GO:0043388;positive regulation of DNA binding;5.0;0.7090535922965819;0.6447678080092112;8.578702127993445;32.525455185636034;5.825829909099042;0.0010885977140540058;0.5881742243410422;[HMGB2, MYOCD, TGFB1, EGF, MMP9, IFNG]
GO:0045840;positive regulation of mitotic nuclear division;8.0;0.7140352122741334;0.7320176061370667;9.138976027173417;276.06341799230654;5.75172193694532;0.009239594159256459;0.6691433273378073;[TGFA, PHB2, NUP62, SH2B1, PDGFRB, RANBP2, RANBP1, TGFB1, EGF, BTC, IL1B, CD28]
GO:0048754;branching morphogenesis of an epithelial tube;6.0;0.7436939687323844;0.6949672969563367;8.8813098506619;51.7127811195946;4.956792062075433;0.0017307802455913577;0.5766108891590862;[NRP1, PLXND1, PHB2, HOXA11, HHEX, HOXA5, PAX2, SFRP2, COL4A1, ENG, PAK1, TGFB1, EGF, PPP1CA]
GO:0042059;negative regulation of epidermal growth factor receptor signaling pathway;8.0;0.8436909121759173;0.7968454560879586;9.417215158824915;234.05310184950287;6.113511981550823;0.00783354668478672;0.6876452870438905;[NUP62, EGF, HGS]
GO:0042730;fibrinolysis;9.0;1.0;0.896240625180289;9.628524252492122;252.8988266382142;6.7325511899570465;0.008464296133413719;0.740543606130341;[PROS1, GP1BA]
GO:0090370;negative regulation of cholesterol efflux;9.0;1.0;0.896240625180289;9.628524252492122;184.35455179279643;8.390779266560578;0.006170180940179963;0.8253454670833372;[EGF]
GO:0051048;negative regulation of secretion;6.0;0.5318528234273745;0.5890467243038318;7.102795608183866;46.36667726786087;4.478756261132433;0.001551850960854928;0.552164116067923;[FMR1, TNF, IL13RA2, GHSR, IL1R2, F2R, NLRP3, DRD4, CYP4F2, INHBA, IFNA2, PTPN22, CCR2, ANXA1, RAB33B, CEACAM1, BANK1, IL1B, TLR8, TLR6, GNAI2, CNR1, EGF, LILRB1, NLRP12, FCGR2B, LGR4]
GO:0000187;activation of MAPK activity;13.0;0.811012628672052;0.8680612791036626;9.526741558182179;3706.2450018205795;4.759793790865545;0.12404468480698592;0.705971040585548;[, LRRK2, TNF, GHR, PROK2, TNFSF11, MAP4K1, MAP2K2, SYK, DUSP6, IL1B, KIT, TLR4, C5AR1, FPR1, CXCR4, TGFA, IQGAP3, NTF3, CCL19, DRD4, MAP2K6, EGF, MAPK14, CD40LG, CSPG4, PKN1]
GO:0000186;activation of MAPKK activity;13.0;0.8259837884571596;0.8755468589962163;9.54300207905396;3706.2450018205795;5.845247994956144;0.12404468480698592;0.7614812190615239;[LRRK2, EGF, F2R, ADAM9]
GO:0045893;positive regulation of transcription, DNA-templated;10.0;0.5159906454948852;0.673236334608363;8.141425192250265;1208.1179641469014;2.4745772039531437;0.04043462102441837;0.5417910051506925;[PID1, SPIB, AKT1, MEF2A, MEF2C, PADI2, ATF3, JUN, JAG1, JUP, FOS, MMP12, STAT4, ATAD2, PSMC6, PSMC2, LGR4, CCNT2, RUVBL2, BLM, FOXO1, NFKB1, CXCL10, CIITA, HHEX, PPP1R12A, E2F5, E2F7, POU2AF1, CCNH, TNFSF11, SFRP2, EGR1, EGR2, EGR3, CD28, BRCA2, CD3D, RGMA, IL1B, IL17A, CD86, CD80, CCNE1, HMGA1, INHBA, TCF4, HMGB2, ARHGEF10L, NUP62, MYOCD, PSRC1, ELF3, CREB5, TAF9, EGF, MAPK14, CD4, RAN, EHF, MYB, HOXA3, HOXA7, HOXA5, HOXB9, HOXB4, HOXB3, HOXB2, HOXB7, HOXB5, NUP85, PRDM16, NKX2-3, NFE2, FZD5, TGFB1I1, PAX5, PAX2, ENG, EPCAM, NR1H2, GTF2H1, PF4, PLXND1, TNF, CDH1, MEN1, MAP2K2, F2R, COPS5, MAFF, LBH, EMILIN1, RFC1, CHUK, SMARCD3, CEBPE, KLF1, KLF5, CHEK1, RPS6KA1, DPF3, SLC11A1, EBF1, FLT3LG, RUNX2, BEX1, NHLH2, BCL11B, IFNA2, PRL, RHOG, TLR4, TLR2, LILRB1, GRHL2, CAMK4, ARID4A, ARID4B, HOXA11, HOXA10, ADRB2, NLRP3, TGFB1, NR4A2, NFKBIA, NR4A1, SLC40A1, CKAP2, DCN, DNM2, DLL1, MEIS2, MEIS1, RBMX]
GO:0071377;cellular response to glucagon stimulus;8.0;1.0;0.875;9.628524252492122;462.69925393661634;6.558197802812269;0.015486127626965131;0.7103865406232063;[ADCY9, PRKAR1B, PRKAR2B, ARG1, GLP2R, PRKACB]
GO:0007409;axonogenesis;8.0;0.6873818243518346;0.7186909121759173;8.667113085337498;64.60914726719044;4.956792062075433;0.0021624100145753813;0.6284905765689417;[NRP1, STMN1, EPHB1, DCC, PAX2, DSCAML1, SLITRK6, LINGO1, GP5, PTK2, NR4A2, LRFN4, OGN]
GO:0002092;positive regulation of receptor internalization;9.0;0.9326813400603323;0.8625812952104552;9.585964638073326;393.55365953464764;6.599019797332524;0.013171886809326083;0.7337148045016781;[SYK, EGF, FMR1, NTF3, SELE]
GO:0000902;cell morphogenesis;4.0;0.6260725219892441;0.563036260994622;7.923776160253697;43.26261951924051;4.420487353008457;0.0014479609414792109;0.47606392880653703;[CYFIP1, COL12A1, SPINT2, CDH5, C1GALT1C1, CDH3, CDH1, MEF2C, ACTN1, COL23A1, CLDN3, SLC1A3, EPB41L5, NCKAP1L, ST14, BCL11B, BCL6, NOX4, NRP1, COL14A1, GP1BA, PALLD, COL6A3, PDPN, SLITRK6, FLNA, LAMB1, MAPK14, GRHL2, TEK]
GO:0051260;protein homooligomerization;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;42.032160359171186;4.056761851073058;0.00140677858073304;0.5305833023127396;[CDA, KCNG2, TCL1A, TNFSF11, MIF, OLFM4, CLDN3, BLM, MGST1, CD79B, CD79A, NACC2, VASP, CAV1, CD3G, CD3E, CD3D, ALAD, EMILIN1, FCER1G, KCND2, VWF, ARG1, NUP54, ACPP, FBP1, COLEC12, NLGN1, HM13, KCNA5, NLRC4, SAMHD1, PLN, GCH1, RAD51, P2RX1, IMPDH2, GOPC, CD247, RBMX]
GO:0021940;positive regulation of cerebellar granule cell precursor proliferation;7.0;1.0;0.8509193652572005;9.628524252492122;202.6652060662171;9.083926447120524;0.006783022060192384;0.8154717862087246;[EGF]
GO:0090263;positive regulation of canonical Wnt signaling pathway;8.0;0.8259837884571596;0.7879918942285797;9.417215158824915;236.52854047757646;5.244474134527214;0.007916397387918217;0.6432026511327102;[LRRK2, RUVBL1, JUP, EGF, CAV1, NFKB1, SULF2, SFRP2, LGR4, NAIP]
GO:0046425;regulation of JAK-STAT cascade;8.0;0.7586651285174919;0.754332564258746;9.158520623246385;46.16872612457469;4.77312732173501;0.0015452257142336023;0.6190979532066485;[IFNA5, IFNA4, IFNA7, IFNA2, LRRC4, PRL, IFNA8, GHR, PPP2R1A, LRRTM4, IL6R, IFNA14, IFNA16, F2R, GP1BA, DCN, IFNG, HGS, KIT, IFNA10, LRRC19, FLRT2, CCL5, FYN, IFNA21, LYN, EGF, CAV1, PODN, GH1]
GO:0045652;regulation of megakaryocyte differentiation;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;68.9575807315309;5.845247994956144;0.0023079481692908138;0.6498456195510879;[HMGB2, NFE2, MEF2C, GP1BA, PRKCQ, MYL9, PF4]
GO:0046426;negative regulation of JAK-STAT cascade;9.0;0.9326813400603323;0.8625812952104552;9.577230958104572;286.97803335492995;5.845247994956144;0.009604896512927369;0.6951668794741764;[LRRC19, CAV1, LRRC4, GP1BA, PODN, DCN, FLRT2, HGS, PPP2R1A, LRRTM4]
GO:0006888;ER to Golgi vesicle-mediated transport;6.0;1.0;0.8231203125901445;9.628524252492122;49.13394272044514;4.493869898942481;0.001644468845175705;0.5529370282083849;[, PROS1, NRBP1, COPB2, TGFA, SPTA1, SERPINA1, SPTAN1, TMED6, F5, RAB33B, GOPC]
GO:2000008;regulation of protein localization to cell surface;6.0;0.8933024483968273;0.7697715367885581;9.377209824211215;29.0551629072873;6.166155715036245;9.724501545579579E-4;0.6384578026126634;[TNF, AKT1, FCER1G, EGF, GOPC, CD247]
GO:0097338;response to clozapine;5.0;1.0;0.7902410118609202;9.628524252492122;76.04989429310582;9.083926447120524;0.002545321521528919;0.7547934328124444;[PRKAR2B, PRKACB]
GO:0016486;peptide hormone processing;7.0;0.7980440201809971;0.7499413753476991;9.328419660041783;182.775265034119;6.280566066213989;0.006117323633632836;0.6721078059595746;[ENPEP, ACE, MME, PCSK6, CTSG]
GO:0051897;positive regulation of protein kinase B signaling;8.0;1.0;0.875;9.628524252492122;238.41769229280743;4.7664383335842135;0.007979625599047746;0.6187558780415471;[CD86, CD80, TNF, FGF5, TNFSF11, CCR7, PDGFRB, GAB1, VAV1, BTC, LCK, KIT, CHI3L1, HBEGF, ENG, CD19, FYN, CCL19, ICOS, TGFB1, TRAT1, EGF, PTK2, LIN28A, CD28, NOX4, TEK]
GO:0072659;protein localization to plasma membrane;6.0;0.7866048967936545;0.7164227609869718;9.260799472366804;65.42666064804821;4.677207199856271;0.002189771451718415;0.5623129063031725;[PLEKHF1, TNF, CDH1, FCER1G, GOLPH3L, TTC7B, ATP1B1, PKP3, TSPAN33, FLNA, TSPAN5, JUP, RAMP1]
GO:0010389;regulation of G2/M transition of mitotic cell cycle;8.0;0.7369933605727446;0.7434966802863723;8.986670366319727;58.92720908338202;4.74012102526684;0.001972240656975688;0.6174100096703167;[PPP2R1A, MSH6, BLM, PRKAR2B, NAE1, CDC6, TOPBP1, TUBG1, RAD51C, SMARCD3]
GO:0030335;positive regulation of cell migration;7.0;0.5846489169746516;0.6432438237445264;8.22453031427283;157.26390226612122;3.6656062881777913;0.005263481280523835;0.5383786413027378;[MYLK, LGALS3, C3AR1, AKT1, IL1R1, ACTN4, PFN1, FPR2, PLA2G7, EPB41L5, PDGFD, PDGFC, NCKAP1L, S100A14, PLCG1, ELANE, LYN, CCR1, JUN, TNFSF14, PLK2, PPBP, PTK2, NOX4, NRP1, NRP2, RAC2, CTSH, CCR7, CCR6, CCR2, ANXA1, ANXA3, GAB1, CEACAM6, IL1B, KIT, HBEGF, PTAFR, PTGS2, GNAI2, PAK1, GPNMB, CXCR2, PDPN, NTF3, FLNA, CCL19, CCL20, PF4, SEMA5B, CXCL13, TNF, SLC8A1, CXCL16, PYCARD, IL6R, PDGFRB, F2R, ADAM9, CD274, CD151, C5AR1, CORO1A, TGFB1, CXCL10, CXCL11, CXCL12, PTPRC, DOCK5, CXCL6, CXCL9, TNFAIP6, LAMC2, CXCL1, CXCL3, CXCL2, CXCL5, MMP9, FGR, IFNG, XCL1, P2RY6, CCL8, CCL7, CCL5, CCL4, CCL1, EGF, SEMA4B, LAMB1, MAPK14, TEK]
GO:2000060;positive regulation of ubiquitin-dependent protein catabolic process;10.0;0.811012628672052;0.8207473261969463;9.483342242647623;1661.590298646008;5.192106149009898;0.055611931961498426;0.6807655617789147;[LRRK2, AKT1, EGF, PLK2, CAV1, PTK2, CCDC22]
GO:0019934;cGMP-mediated signaling;8.0;0.9326813400603323;0.8413406700301662;9.523163736834295;28.507808342730176;7.069023426578259;9.541306898693577E-4;0.7365101867784198;[EDNRB, PRKAR1B, PRKAR2B, CD36]
GO:0007597;blood coagulation, intrinsic pathway;6.0;1.0;0.8231203125901445;9.628524252492122;55.78978942234946;6.943860283624253;0.0018672340444153065;0.6782296504172152;[GP9, VWF, GP1BB, F11, GP1BA, GP5]
GO:0044332;Wnt signaling pathway involved in dorsal/ventral axis specification;8.0;1.0;0.875;9.628524252492122;31.415129658942366;7.9853141584524145;0.0010514361179036673;0.7833693374183408;[FZD5, EGF]
GO:0045741;positive regulation of epidermal growth factor-activated receptor activity;12.0;0.9326813400603323;0.9144609826203107;9.611429819132821;2972.107935112762;7.292166977892469;0.09947377786474029;0.8210420709600095;[EGF, TGFA]
GO:0007354;zygotic determination of anterior/posterior axis, embryo;6.0;1.0;0.8231203125901445;9.628524252492122;41.01780337135347;9.777073627680469;0.001372828965212802;0.8231203125901445;[PCSK6]
GO:0045746;negative regulation of Notch signaling pathway;7.0;0.9326813400603323;0.8172600352873667;9.56398573135455;188.1075192762445;6.193554689224359;0.006295789384399518;0.6676580400938822;[EGF, NFKBIA, BCL6]
GO:0006469;negative regulation of protein kinase activity;10.0;0.6835726970475526;0.7570273603846966;9.223059144383958;1097.0598301796;4.243684138952949;0.03671760522636433;0.6322632160784685;[PYCARD, PPP2R1A, AKT1, MEN1, PAQR3, TSC2, SFRP2, PRKAR1B, FLRT2, PRKAR2B, SFN, LYN, CAV1, PTPRC, PKIG, CDKN1A, LRRC4, TNFAIP3, PTPN22, HHEX, DUSP10, LRRTM4, NUP62, DUSP2, MYOCD, DUSP1, IRAK3, GP1BA, DUSP6, DCN, CEACAM1, IL1B, LRRC19, CDKN2C, PODN, PTPN6, PKN1]
GO:0002576;platelet degranulation;8.0;1.0;0.875;9.628524252492122;39.85546922145481;4.956792062075433;0.0013339266872485146;0.6284905765689417;[ORM1, SERPINA1, PROS1, F13A1, LAMP2, TIMP3, CD36, TIMP1, VWF, ACTN1, ANXA5, ACTN4, F5, PECAM1, TLN1, VCL, STXBP2, FLNA, LYN, TGFB1, EGF, LHFPL2, PPBP, CD9, PF4]
GO:0030449;regulation of complement activation;8.0;0.6873818243518346;0.7186909121759173;9.298282565621545;245.7676390307622;5.076593261888053;0.008225621701844479;0.6346172154986847;[C1QA, PROS1, C5AR1, IGHG1, IGKC, CD19, IGLV1-44, C3AR1, CR2, CR1, IGKV3-20]
GO:0000086;G2/M transition of mitotic cell cycle;5.0;1.0;0.7902410118609202;9.628524252492122;43.44612409677276;4.981283082083729;0.0014541026745458175;0.5449840603320351;[CDKN1A, PPP2R1A, SKP2, TUBG1, CIT, DNM2, MELK, PKMYT1, PRKAR2B, WEE1, CDK14]
GO:0019221;cytokine-mediated signaling pathway;6.0;0.6039883530135606;0.6251144890969248;7.604142487995313;26.50247477320489;3.309374901576116;8.87013979980389E-4;0.49236189895841853;[AKT1, FPR1, FLRT2, HLA-DQA1, HLA-DRB4, HLA-DRB1, CDKN1A, LRRC4, TIMP1, HLA-DPA1, ANXA1, FOS, FCER2, HLA-DQB1, CCL13, LRRC19, PTAFR, PTGS2, ALOX5, STAT4, CCL19, CCL18, IL12RB1, IL12RB2, CCL23, CCL20, HLA-DPB1, PF4, CSF3R, F13A1, IL5RA, CXCL13, TNF, PYCARD, IGHG1, IL13RA2, IFNA14, IFNA16, IFNA10, TNFRSF11A, FOXO1, TNFRSF17, IFNA21, TNFRSF10C, TNFRSF10B, NFKB1, CXCL10, CXCL11, CXCL12, BCL6, LCN2, HLA-DRA, MYD88, CIITA, ITGAM, FASLG, TNFSF13B, CHUK, TNFRSF1B, XCL1, CX3CR1, IL2RG, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1, FYN, FCGR1B, IL2RB, PTPN6, TNFSF11, ACSL1, IL1R1, IL1R2, FLT3LG, MIF, INPP5D, CCR10, CCR1, EGR1, TNFSF14, TNFSF12, PPBP, SDC1, IFNA5, IFNA4, IFNA7, TNFRSF13B, IFNA2, IFNA8, CCR9, CCR7, CCR6, CD36, CCR5, CCR2, SYK, GP1BA, IL17RB, VAV1, HCK, CEACAM1, IL1B, KIT, RHOU, CXCR5, CXCR4, CXCR6, CXCR1, CXCR2, PODN, CD40LG, IL18R1, IL17A, CD86, CD80, IL18RAP, CCRL2, IL6R, PRTN3, CSF2RB, TGFB1, NFKBIA, CXCL6, CXCL9, CXCL1, CXCL3, CXCL2, CXCL5, GHR, LRRTM4, IRAK3, MMP9, DCN, IFNG, SAMHD1, NCAM1, CD4, LTBR]
GO:0060070;canonical Wnt signaling pathway;8.0;0.6729672293956388;0.7114836146978194;8.391761625343195;31.415129658942366;5.233778845410465;0.0010514361179036673;0.6426556935498979;[LRRK2, CDH3, FZD5, EGF, TMEM64, NR4A2, HOXB9, SFRP2, SDC1, LGR4]
GO:0010951;negative regulation of endopeptidase activity;10.0;0.7671156992804218;0.7987988615011312;9.446202695698167;500.3238742612354;4.2676852910524925;0.016745389809270216;0.6334906361130068;[PROS1, SPINT2, RPS6KA1, AKT1, POR, SFRP2, SPINT1, SLPI, NAIP, SFN, TNFSF14, TNFRSF10C, CRIM1, TNFRSF10B, DHCR24, SERPINA1, TIMP3, TIMP1, CR1, SERPINB9, TNFRSF1B, MMP9, PAX2, COL6A3, LTF, SERPINB10, NLRC4, PTGS2, SPOCK3]
GO:0038128;ERBB2 signaling pathway;9.0;0.8653626801206646;0.8289219652406215;9.36615998802463;32.38857880465376;6.343086423195323;0.0010840165847632744;0.7206263598461826;[PTPRR, EGF, GAB1, BTC, HBEGF]
GO:0009100;glycoprotein metabolic process;5.0;0.6162540371078848;0.5983680304148626;8.375761283996754;94.72373048927207;4.981283082083729;0.0031703180136531234;0.5449840603320351;[PCSK6, NDST3, HS3ST3B1, COL11A1, ADAMTS12, SULF2]
GO:0007167;enzyme linked receptor protein signaling pathway;6.0;0.5334320500414464;0.5898363376108677;7.041834908394179;26.50247477320489;3.253511321530957;8.87013979980389E-4;0.48950503287698693;[CYFIP1, SLA2, EPS8, STMN1, AKT1, EPHB1, RUNX2, BTC, BTK, EPHA3, SDC2, TGFA, SLC30A10, FLRT2, PDGFD, PDGFC, NCKAP1L, PLCG1, PAG1, LYN, EGR1, JUN, GP6, PTK2, NRP1, ITK, PTPRR, NRP2, PTPRK, CD3E, SYK, GAB1, FOS, VAV1, RGMA, HCK, KIT, HBEGF, ENG, PAK1, NTF3, SORT1, USP9Y, SORBS1, SULF2, ZYX, NCF4, CTGF, FGF5, CDH5, EFEMP1, GRAP2, AP2M1, PDGFRB, TSC2, KIF16B, COL4A1, ADAM9, BLK, RASGRP4, FOXO1, STAP1, TGFB1, CAV2, CRIM1, INHBA, BMX, GH1, CSPG4, GHR, TMEM100, BLNK, MMP9, TGFBR3, FGR, ZAP70, LCK, ESRP1, LCP2, REPS2, POLR2E, FYN, CSK, POLR2I, POLR2J, POLR2K, POLR2L, TRAT1, EGF, MAPK14, CD4, CD7, TEK]
GO:1900127;positive regulation of hyaluronan biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;589.7686013946351;8.390779266560578;0.019739024331396862;0.8253454670833372;[EGF, NFKB1]
GO:0006631;fatty acid metabolic process;7.0;0.5408746917014966;0.6213567111079488;7.849668188099975;91.0232021896581;4.037280715501235;0.0030464646617242943;0.5573860888006872;[, SCARB2, ACSL1, MIF, POR, SLC27A2, MGST1, PRKAR2B, CYP4F2, CYP4F3, TBXAS1, TECR, ETFA, GHR, ACADM, HIBCH, ELOVL4, ELOVL6, NDUFS6, HSD17B4, PTGS2, ALOX5, PNPLA8, MAPK14, SCD, NDUFAB1, PLP1]
GO:0070371;ERK1 and ERK2 cascade;10.0;1.0;0.9152410118609203;9.628524252492122;233.3964595037646;6.481236761676141;0.007811569456414605;0.7466917612613706;[MAP2K2, EGF, IQGAP3, TNFSF11, CTSH]
GO:0070493;thrombin-activated receptor signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.976932752798508;7.57984905034425;9.028936615729279E-4;0.710754145523778;[F2R, GP1BA, F2RL3]
GO:0097711;ciliary basal body-plasma membrane docking;5.0;1.0;0.7902410118609202;9.628524252492122;21.38880323109876;5.223196736079928;7.158639954716971E-4;0.5573555358475362;[PPP2R1A, TUBG1, PRKAR2B]
GO:0010800;positive regulation of peptidyl-threonine phosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;778.6672313762616;6.375876246018314;0.026061291479152104;0.7413036195908642;[TGFB1, EGF, AZU1, CHI3L1]
GO:0050900;leukocyte migration;5.0;0.6023560406934092;0.5914190322076249;8.01908634005802;26.939797568556347;3.896540641279769;9.016507803758389E-4;0.4895102814636384;[CSF3R, PROS1, SIRPG, CXCL13, CXCL16, VPREB3, EPS8, LGALS3, VPREB1, EDNRB, C3AR1, TNFSF11, IL6R, SLC16A3, CD177, CXADR, ATP1B2, MIF, ATP1B1, PRTN3, S100A8, GYPA, CALCA, SDC2, C5AR1, FPR1, FPR3, FPR2, TNFRSF11A, CORO1A, NUP85, INPP5D, IGLV1-44, NCKAP1L, PLCG1, IGHA1, ELANE, NKX2-3, LYN, CCR1, TGFB1, GPR15, CAV1, TNFRSF10B, AZU1, DEFA1, PPBP, GP6, SELE, CXCL10, CXCL11, SDC1, IGKV3-20, IGHM, CXCL6, CXCL9, ITGAM, CXCL1, SLC7A11, CXCL3, CXCL2, TREM1, CXCL5, PDE4B, OLR1, FFAR2, CCR7, CCR6, CCR5, CCR2, ANXA1, FCER1G, SYK, MMP9, VAV1, SLC7A5, ZAP70, HCK, CEACAM1, SLC7A7, SLC7A8, CEACAM6, LCK, IL1B, KIT, PECAM1, XCL1, CX3CR1, CCL13, CXCR5, CXCR4, CCL8, IGKC, CXCR1, CCL7, EPCAM, CCL5, CXCR2, CCL4, CCL2, CCL1, FYN, CD58, CCL19, CCL18, JAM2, JAM3, CCL23, CCL20, CD2, NLRP12, PTPN6, TEK, CD244, PF4]
GO:0030510;regulation of BMP signaling pathway;11.0;0.7508913569872202;0.8078746308232723;9.360260265897443;322.7842812572362;5.334422371190153;0.010803299406686577;0.705231560468336;[LRP2, PCSK6, SFRP2, ENG]
